Aldevron has signed a long-term agreement with Sarepta Therapeutics to provide the gene-transfer vehicles used in Sarepta’s gene therapies that are being tested in ongoing and future clinical trials, as well as for future commercialization. Sarepta Therapeutics is a leading pharmaceutical developing precision genetic therapies for rare diseases, and has begun developing a gene therapy program for Charcot-Marie-Tooth (CMT) … Continue reading Sarepta, Aldevron Partnering to Develop Gene Therapies for CMT, Other Rare Diseases